Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Role of Antigen Carbohydrate 125 in Modulating Soluble ST2, Prognostic-Related Effects in Acute Heart Failure

  • Martí-Martínez, Arancha
  • Núñez, Julio|||0000-0003-1672-7119
  • López Escribano, Herminio
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Mollar, Anna
  • Peiró, Marta
  • Sanchis, Juan|||0000-0003-0797-8709
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Carratala, Arturo|||0000-0003-4513-7214
  • Miró, Oscar|||0000-0002-7924-9751
  • Llorens Soriano, Pere|||0000-0002-9291-7179
  • Herrero-Puente, Pablo|||0000-0002-5529-5008
Background: Acute heart failure (AHF) is a complex syndrome associated with high mortality and hospital readmissions, characterized by volume overload and inflammation. Soluble ST2 (sST2) and antigen carbohydrate 125 (CA125) are emerging biomarkers that reflect these processes and may interact to influence long-term outcomes in AHF patients. This study aims to examine the prognostic relationship between sST2 and CA125 in predicting mortality and heart failure (HF)-related hospitalizations in patients with decompensated heart failure. Methods: In a cohort of 635 patients with AHF, we investigated whether the prognostic value of sST2 varies according to CA125 levels (≤35 vs. >35 U/mL). The endpoints were: (a) time to all-cause death, and (b) the combination of time to death or new HF admission. Results: This study of EAHFE registry data shows that the association between sST2 and long-term adverse outcomes (mortality and HF hospitalizations) in patients with AHF was differentially influenced by CA125 concentrations (p-value for interactions = 0.031 and 0.029, respectively). Higher sST2 was associated with the risk of death and the combined risk of death/HF readmission when CA125 was >35 U/mL [HR = 1.02 (CI 95%: 1.01-1.04), p = 0.006 and 1.02 (CI 95%: 1.01-1.03); p = 0.013 per increase in 10 ng/mL, respectively], but not when CA125 was ≤35 U/mL. Conclusions: This study highlights the prognostic interaction between sST2 and CA125 in AHF. Elevated sST2 predicts poor outcomes mainly in patients with high CA125 levels (>35 U/mL), suggesting CA125's role in modulating inflammatory activity in HF. Further research is needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Short-Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure, A Substudy of the Myocardial-IRON Trial

  • del Canto, Irene
  • Santas, Enrique
  • Cardells, Ingrid
  • Miñana, Gema|||0000-0001-8777-2588
  • Palau, Patricia|||0000-0001-5040-0924
  • Llàcer, Pau
  • Facila Rubio, Lorenzo|||0000-0003-1402-4364
  • López-Vilella, Raquel
  • Almenar Bonet, Luis|||0000-0002-7710-361X
  • Bodi, Vicente|||0000-0001-6425-5828
  • López-Lereu, Maria P.
  • Monmeneu, Jose V.
  • Sanchis, Juan|||0000-0003-0797-8709
  • Moratal, David|||0000-0002-2825-3646
  • Maceira, Alicia M.|||0000-0001-5486-4232
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Chorro, Francisco J.
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
The mechanisms explaining the clinical benefits of ferric carboximaltose (FCM) in patients with heart failure, reduced or intermediate left ventricular ejection fraction, and iron deficiency remain not fully clarified. The Myocardial-IRON trial showed short-term cardiac magnetic resonance (CMR) changes suggesting myocardial iron repletion following administration of FCM but failed to find a significant increase in left ventricular ejection fraction in the whole sample. Conversely, the strain assessment could evaluate more specifically subtle changes in contractility. In this subanalysis, we aimed to evaluate the effect of FCM on the short-term left and right ventricular CMR feature tracking derived strain. This is a post hoc subanalysis of the double-blind, placebo-controlled, randomized clinical trial that enrolled 53 ambulatory patients with heart failure and left ventricular ejection fraction <50%, and iron deficiency [Myocardial-IRON trial (NCT03398681)]. Three-dimensional left and 2-dimensional right ventricular CMR tracking strain (longitudinal, circumferential, and radial) changes were evaluated before, 7 and 30 days after randomization using linear mixed-effect analysis. The median (interquartile range) age of the sample was 73 years (65-78), and 40 (75.5%) were men. At baseline, there were no significant differences in CMR feature tracking strain parameters across both treatment arms. At 7 days, the only global 3-dimensional left ventricular circumferential strain was significantly higher in the FCM treatment-arm (difference: -1.6%, P =0.001). At 30 days, and compared with placebo, global 3-dimensional left ventricular strain parameters significantly improved in those allocated to FCM treatment-arm [longitudinal (difference: -2.3%, P <0.001), circumferential (difference: -2.5%, P <0.001), and radial (difference: 4.2%, P =0.002)]. Likewise, significant improvements in global right ventricular strain parameters were found in the active arm at 30 days (longitudinal [difference: -3.3%, P =0.010], circumferential [difference: -4.5%, P <0.001], and radial [difference: 4.5%, P =0.027]). In patients with stable heart failure, left ventricular ejection fraction <50%, and iron deficiency, treatment with FCM was associated with short-term improvements in left and right ventricular function assessed by CMR feature tracking derived strain parameters. URL: ; Unique identifier: NCT03398681.